Neurophysin-related surface antigen (NRSA)

Neurophysin-related surface antigen (NRSA) is a tumor-specific cell surface marker predominantly found on small-cell lung cancer (SCLC) cells. It represents the unprocessed or partially processed precursor of the hormone vasopressin, known as pro-vasopressin (pro-VP) or pro-pressophysin. In normal physiology, pro-vasopressin is synthesized in the hypothalamus and enzymatically cleaved into arginine vasopressin, neurophysin II, and copeptin before secretion. However, in SCLC and some breast cancers, the vasopressin gene is ectopically expressed, and the resulting pro-hormone is uniquely localized to the plasma membrane rather than being fully processed and secreted. This surface expression allows NRSA to serve as a target for monoclonal antibodies such as MAG-1, which binds to the C-terminal region of the precursor. Targeting NRSA with antibodies can lead to internalization and the induction of apoptosis, making it a promising candidate for both diagnostic imaging and targeted therapy. The antigen is expressed in the majority of SCLC cases, including primary, metastatic, and recurrent disease, providing a broad therapeutic window. Preclinical studies have demonstrated that anti-NRSA antibodies can significantly impair tumor growth in xenograft models. While the normal hormone is vital for water balance, the tumor-specific surface localization of the precursor minimizes off-target effects in healthy tissues. Overall, NRSA represents a novel and highly specific target for the treatment of aggressive neuroendocrine malignancies.

Other names

Pro-vasopressinPro-pressophysinCopeptinVasopressin-associated glycopeptideVAGNeurophysin IIGRSAGlycopeptide-related surface antigen

Monoclonal antibody binding to the cell surface antigen followed by internalization and induction of apoptosis or delivery of cytotoxic payloads.